Reported about 16 hours ago
UBS has lowered its price target for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) from $633 to $560 while maintaining a Neutral rating. The adjustment follows mixed corporate updates and recent pipeline developments. Key changes include results from the Phase 2 COURAGE study and Phase 3 AERIFY trials, along with a significant acquisition of 23andMe. Despite Regeneron's strategic expansions beyond its ophthalmology focus, concerns over the weakening Eylea franchise continue to affect market sentiment.
Source: YAHOO